Use of von Willebrand diseased kidney as donor in a pig-to-primate model of xenotransplantation

被引:25
作者
Meyer, C
Wolf, P
Romain, N
Ravanat, C
Roussi, J
Beller, JP
Imbs, P
Chenard, MP
Fabre, M
Kieny, R
Bonneau, M
Drouet, L
Cazenave, JP
Soulillou, JP
Azimzadeh, A
机构
[1] Fdn Transplantat, Chirurg Expt Lab, F-67200 Strasbourg, France
[2] INSERM, U311, Establissement Transfus Sanguine Strasbourg, F-67065 Strasbourg, France
[3] Inst Transplantat & Rech Transplantat, INSERM, U437, F-44093 Nantes 01, France
[4] Hop St Louis, INSERM, U353, F-75475 Paris, France
[5] Univ Strasbourg 1, Fac Med, Serv Cent Microscopie Elect, F-67085 Strasbourg, France
[6] INRA, UEPSD, F-78351 Jouy En Josas, France
关键词
D O I
10.1097/00007890-199901150-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The coagulation process in hyperacute and delayed xenograft rejection is essential and depends upon platelet adhesion and aggregation. The initial binding of platelets to the damaged endothelium is due to the interaction of the platelet receptor glycoprotein Ib with von Willebrand factor (vWF), which is present on activated endothelial cells and bound to the subendothelial matrix. We hypothesized that the use of organs from animals with homozygous von Willebrand disease (vWD), severely deficient in vWF, might prevent the thrombosis encountered in delayed xenograft rejection. Methods. Ten baboons were treated by extracorporeal immunoadsorption of xenoreactive natural antibodies (XNA) through the donor pig liver to inhibit hyperacute rejection and received heterotopic vWD or control pig kidney xenografts. XNA levels, coagulation, and platelet activation markers were studied, and specimens of rejected kidneys were analyzed histologically. Results. Although XNA depletion was comparable in both groups, neither kidney function nor survival times of control (n=5) or vWD (n=5) porcine kidneys showed any difference. Platelet and coagulation activation was evidenced in both groups after surgery and at rejection time. Immunohistochemical analysis revealed a weak endothelial vWF immunostaining in the rejected vWD kidneys, whereas it was undetectable in the nongrafted vWD kidneys, suggesting the deposition of baboon plasma vWF on the porcine vessels. Conclusions. The use of vWD organs did not improve the survival time of grafted kidneys in this xenotransplantation model. Further studies on the use of vWD organs, in association with other therapeutic approaches, such as complement inhibition, are nevertheless necessary to evaluate the usefulness of vWF deficiency as an adjunctive therapy to decrease the coagulation process during xenograft rejection.
引用
收藏
页码:38 / 45
页数:8
相关论文
共 32 条
[1]   Removal of primate xenoreactive natural antibodies by extracorporeal perfusion of pig kidneys and livers [J].
Azimzadeh, A ;
Meyer, C ;
Watier, H ;
Beller, JP ;
Chenard-Neu, MP ;
Kieny, R ;
Boudjema, K ;
Jaeck, D ;
Cinqualbre, J ;
Wolf, P .
TRANSPLANT IMMUNOLOGY, 1998, 6 (01) :13-22
[2]   Comparative study of target antigens for primate xenoreactive natural antibodies in pig and rat endothelial cells [J].
Azimzadeh, A ;
Wolf, P ;
Thibaudeau, K ;
Cinqualbre, J ;
Soulillou, JP ;
Anegon, I .
TRANSPLANTATION, 1997, 64 (08) :1166-1174
[3]   ENDOTHELIAL-CELL ACTIVATION AND THROMBOREGULATION DURING XENOGRAFT REJECTION [J].
BACH, FH ;
ROBSON, SC ;
FERRAN, C ;
WINKLER, H ;
MILLAN, MT ;
STUHLMEIER, KM ;
VANHOVE, B ;
BLAKELY, ML ;
VANDERWERF, WJ ;
HOFER, E ;
DEMARTIN, R ;
HANCOCK, WW .
IMMUNOLOGICAL REVIEWS, 1994, 141 :5-30
[4]   BARRIERS TO XENOTRANSPLANTATION [J].
BACH, FH ;
ROBSON, SC ;
WINKLER, H ;
FERRAN, C ;
STUHLMEIER, KM ;
WRIGHTON, CJ ;
HANCOCK, WW .
NATURE MEDICINE, 1995, 1 (09) :869-873
[5]  
BACH FH, 1995, TRANSPLANTATION IMMU, P305
[6]  
BOWIE EJW, 1973, AM J VET RES, V34, P1405
[7]   Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage [J].
Byrne, G ;
McCurry, KR ;
Martin, MJ ;
McClellan, SM ;
Platt, JL ;
Logan, JS .
TRANSPLANTATION, 1997, 63 (01) :149-155
[8]   Inhibition of platelet integrin GPIIbIIIa prolongs survival of discordant cardiac xenografts [J].
Candinas, D ;
Lesnikoski, BA ;
Hancock, WW ;
Otsu, I ;
Koyamada, N ;
Dalmasso, AP ;
Robson, SC ;
Bach, FH .
TRANSPLANTATION, 1996, 62 (01) :1-5
[9]  
COLLER BS, 1995, THROMB HAEMOSTASIS, V74, P302
[10]  
COOPER DKC, 1992, CLIN TRANSPLANT, V6, P178